Managing Myeloma Kidney
Authors: Morie A. Gertz
Journal: Annals of Internal Medicine (2005)

Editorials6 December 2005Managing Myeloma KidneyMorie A. Gertz, MDMorie A. Gertz, MDFrom Mayo Clinic, Rochester, MN 55905.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-11-200512060-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail It is estimated that, in 2005, multiple myeloma will be diagnosed in 15 980 persons and 11 300 persons will die of it, constituting 2% of all deaths from cancer (1). Although myeloma bone disease and anemia are the primary manifestations of the disorder, only 52% of patients have normal renal function at diagnosis. At presentation, the serum creatinine level is between 114 µmol/L (1.3 mg/dL) and 175 µmol/L (2.0 mg/dL) in 29% of patients and 176 µmol/L or more (≥2.0 mg/dL) in 19% of patients. Therefore, nearly 8000 patients per year will present their physicians with the challenging problem of managing ...References1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30. [PMID: 15661684] CrossrefMedlineGoogle Scholar2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33. [PMID: 12528874] CrossrefMedlineGoogle Scholar3. Rabb H, Gunasekaran H, Gunasekaran S, Saba SR. Acute renal failure from multiple myeloma precipitated by ACE inhibitors. Am J Kidney Dis. 1999;33:5. [PMID: 10074605] CrossrefMedlineGoogle Scholar4. Taparia BN, Bahel B, Shah BV, Ashavaid TF, Kapadia A, Sirsat RA. Renal involvement in multiple myeloma. J Assoc Physicians India. 1996;44:240-2. [PMID: 9251392] MedlineGoogle Scholar5. Keller LS, Faull RJ, Smith P, Swift J, Bannister KM, Otto S, et al. Crystalloid deposits in the kidney. Nephrology (Carlton). 2005;10:81-3. [PMID: 15705186] CrossrefMedlineGoogle Scholar6. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med. 2004;128:875-9. [PMID: 15270616] CrossrefMedlineGoogle Scholar7. Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001;158:1859-66. [PMID: 11337384] CrossrefMedlineGoogle Scholar8. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53:207-12. [PMID: 7957804] CrossrefMedlineGoogle Scholar9. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, et al. Plasma exchange when myeloma presents as acute renal failure. A randomized, controlled trial. Ann Intern Med. 2005;143:777-84. LinkGoogle Scholar10. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev. 1999;13:79-90. [PMID: 10414944] CrossrefMedlineGoogle Scholar11. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood. 2004;104:40-2. [PMID: 15010372] CrossrefMedlineGoogle Scholar12. Abbott KC, Agodoa LY. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2001;56:207-10. [PMID: 11597035] MedlineGoogle Scholar13. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65:175-81. [PMID: 11007053] CrossrefMedlineGoogle Scholar14. Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889-93. [PMID: 9759684] CrossrefMedlineGoogle Scholar15. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A, et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma. Br J Cancer. 2001;85:325-32. [PMID: 11487259] CrossrefMedlineGoogle Scholar16. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75:27-33. [PMID: 15946307] CrossrefMedlineGoogle Scholar17. Pasquali S, Cagnoli L, Rovinetti C, Rigotti A, Zucchelli P. Plasma exchange therapy in rapidly progressive renal failure due to multiple myeloma. Int J Artif Organs. 1985;8 Suppl 2 27-30. [PMID: 4055108] MedlineGoogle Scholar18. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988;33:1175-80. [PMID: 3043077] CrossrefMedlineGoogle Scholar19. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990;150:863-9. [PMID: 2183734] CrossrefMedlineGoogle Scholar20. Moist L, Nesrallah G, Kortas C, Espirtu E, Ostbye T, Clark WF. Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. Am J Nephrol. 1999;19:45-50. [PMID: 10085449] CrossrefMedlineGoogle Scholar21. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4:379-98. [PMID: 14671610] CrossrefMedlineGoogle Scholar22. Abraham RS, Clark RJ, Bryant SC, Lymp JF, Larson T, Kyle RA, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem. 2002;48:655-7. [PMID: 11901068] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Morie A. Gertz, MDAffiliations: From Mayo Clinic, Rochester, MN 55905.Disclosures: None disclosed.Corresponding Author: Morie A. Gertz, MD, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPlasma Exchange When Myeloma Presents as Acute Renal Failure William F. Clark , A. Keith Stewart , Gail A. Rock , Marion Sternbach , David M. Sutton , Brendan J. Barrett , A. Paul Heidenheim , Amit X. Garg , and David N. Churchill , and the Canadian Apheresis Group Metrics Cited byKidney diseases associated with Waldenström macroglobulinemiaSafety and efficacy of autologous hemopoietic progenitor cell collection in tandem with hemodialysis in multiple myeloma with myeloma cast nephropathyManaging light chain deposition diseasePlasmapheresisRenal Complications in Multiple Myeloma and Related DisordersThe biology of immunoglobulin free light chains and kidney injuryRenal Lesions Associated With Plasma Cell Dyscrasias: Practical Approach to Diagnosis, New Concepts, and ChallengesRenal Disease Is a Prodrome of Multiple Myeloma: An Analysis of 50 Patients from Eastern IndiaSerum Free-Light Chain Removal by High Cutoff Hemodialysis: Optimizing Removal and Supportive CareUpdate in NephrologyStanley Goldfarb, MDEfficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In Vitro and In Vivo StudiesMultiple MyelomaCast Nephropathy in Myeloma—Does PACAP38, a New Member of the Vasoactive Intestinal Peptide Family, Open a Therapeutic Window? 6 December 2005Volume 143, Issue 11 Page: 835-837 Keywords Blood plasma Chemotherapy Excretion Glomerular filtration rate Kidneys Medical dialysis Multiple myeloma Myeloma Renal failure Ventricular assist devices ePublished: 6 December 2005 Issue Published: 6 December 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...